Brain metastasis are more frequent in EGFR mutated than in wild-type lung adenocarcinoma

Autor:	Marcus Paulo Fernandes Amarante, Antonio C. Buzaid, Fernando C. Maluf, Marcos André Costa, Tercia Tarciane Soares de Sousa, Renata D'Alpino D'Alpino, Jessica Ribeiro Gomes, Marcelo Rocha Cruz, Raphael Brandao Moreira, Carolina Kawamura
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty Pathology Lung business.industry Clinical course Wild type medicine.disease medicine.anatomical_structure Egfr mutation Internal medicine medicine Adenocarcinoma business Brain metastasis
Zdroj:	Journal of Clinical Oncology. 33:e19069-e19069
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.e19069
Popis:	e19069 Background: Brain metastasis (BM) are an event relatively frequent in the clinical course of patients with lung adenocarcinoma. Despite all advances in therapeutical approach, it still has a dismal prognosis. I Identifying subgroups with a higher propensity for BM may be useful to follow those patients closer and therefore offer them earlier brain treatment. We aimed at evaluating whether patients harboring EGFR activating mutations are at a higher risk for BM compared to those without such mutations Methods: We retrospectively reviewed data of 306 patients with lung adenocarcinoma at Sao Jose Hospital in Sao Paulo, Brazil, in the past 5 years. Results: Of the 306 patients analyzed, 52 (16,9%) had EGFR mutations and we identified BM in 19 of them (36,5%). Amongst the other 254 patients, we excluded 151 because records were not well-documented for BM or EGFR status, remaining 103 patients certainly EGFR negative and that underwent a brain image. Of those 103, BM were identified in 26 (25,2%). There ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d44b34bcdd6aaa53e65bf1ea7a10dc4b https://doi.org/10.1200/jco.2015.33.15_suppl.e19069 Zobrazit plný text záznamu